Brian's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership • Q2 2025
Question
Brian, on behalf of Mani Faroohar at Leerink Partners, asked about the recent paydown of the company's credit facility and whether this trend is expected to continue.
Answer
Outgoing CFO Ken Myszkowski explained that the recent paydown was a required one-time event triggered by the cash received from the Sarepta agreement. He clarified that future payments are only required when the company receives cash inflows from milestones, not on a regular schedule.